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ORIGINAL ARTICLE
Outpatient versus inpatient management for superimposed preeclampsia
without severe features: a retrospective, multicenter study
Corina N. Schoena, Sindy C. Morenoa, Gabriele Sacconeb, Nora M. Grahama, Lauren C. Handa,
Giuseppe M. Maruottib, Pasquale Martinellib, Vincenzo Berghellaa and Amanda Romana
aDivision of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Sidney Kimmel Medical College of Thomas Jefferson
University, Philadelphia, PA, USA; bDepartment of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, University
of Naples Federico II, Naples, Italy
ABSTRACT
Purpose: To determine if women with preterm superimposed preeclampsia without severe fea-
tures can be successfully and safely triaged to outpatient management.
Materials and methods: This was a multicenter, retrospective, cohort study of singleton preg-
nancies with superimposed preeclampsia without severe features diagnosed before 37weeks
managed outpatient versus inpatient at Thomas Jefferson University (Philadelphia, PA) and at
University of Naples (Naples, Italy) from January 2008 to July 2015. The attending physician
made the decision to manage outpatient or inpatient at his or her discretion. The primary out-
come was composite maternal morbidity defined as development of at least one of the follow-
ing: severe features, HELLP syndrome, placental abruption, eclampsia, postpartum hemorrhage,
intensive care unit admission, or maternal death. Logistic regression, presented as adjusted odds
ratio (aOR) with the 95% of confidence interval (CI) was performed.
Results: A total of 365 women with superimposed preeclampsia without severe features before
37weeks were analyzed. 198 (54.2%) were managed outpatient, and 167 (45.8%) were managed
inpatient. Women managed as outpatients had a similar rate of maternal morbidity compared to
those managed as inpatients (36.4% versus 41.3%, aOR 0.82, 95%CI 0.55–1.17). Fetuses from
women in the outpatient group had a significantly lower risk of small for gestational age (17.7%
versus 29.3%; aOR 0.53, 95%CI 0.30–0.84), and lower risk of admission to neonatal intensive care
unit (40.4% versus 47.9%; aOR 0.72, 95%CI 0.39–0.95) compared to women managed as
inpatients.
Conclusions: Low risk women with superimposed preeclampsia without severe features can be
triaged to outpatient management without increased maternal morbidity.
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Introduction
Hypertensive disorders during pregnancy, such as
chronic hypertension (CHTN), gestational hypertension,
and preeclampsia, occur in about 20% of pregnancies
[1]. About 1–5% of pregnant women have preexisting
CHTN [1,2]. Women with CHTN are at increased risk for
adverse outcomes including superimposed preeclamp-
sia with or without severe features (SF), eclampsia,
HELLP syndrome, placental abruption as well as fetal
and neonatal complications [2]. Superimposed pree-
clampsia occurs in up to 22–30% of women with
CHTN [2].
Published data regarding the management of
women with CHTN and superimposed preeclampsia
diagnosed preterm are limited [3,4]. Prior to the publi-
cation of the Hypertension in Pregnancy Task Force
by the American College of Obstetricians and
Gynecologists (ACOG), women with superimposed pre-
eclampsia were grouped under one diagnosis, without
regard for severity of disease presentation [4]. This led
to a higher rate of preterm deliveries in this group, as
women may have been managed as severe pree-
clampsia patients, even if features of their disease
were more similar to those with mild preeclampsia
[3,4]. After the publication of ACOG hypertension
guidelines, diagnosis of superimposed preeclampsia
was clarified, allowing for tailored clinical management
and a potential reduction in unnecessary preterm
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deliveries. A qualified recommendation was made to
manage women with superimposed preeclampsia
without SF expectantly until 37 0/7weeks if the
mother and fetus were both stable [4]. There is limited
evidence on expectant management in these cases,
limited to patients managed in a hospital setting [3].
ACOG made no recommendation regarding whether
these women should be managed in the hospital or
can be safely managed in outpatient settings, and
concluded that in women with gestational age of less
than 37weeks “there is a paucity of data to support
outpatient management of superimposed pre-
eclampsia” [4].
Thus, the aim of this study was to describe two
centers experience with outpatient care and determine
if women with preterm superimposed preeclampsia
without SF managed can be safely triaged to out-
patient care without an increase in maternal
morbidity.
Materials and methods
This was a multicenter, retrospective, cohort study.
Clinical records of all consecutive singleton pregnan-
cies with CHTN diagnosed with superimposed pree-
clampsia without SF before 37weeks, who were
referred to the Division of Maternal Fetal Medicine,
Thomas Jefferson University Hospital (Philadelphia,
PA), and the Department of Reproductive Science,
University of Naples Federico II (Naples, Italy) from
January 2008 to July 2015 were collected in a dedi-
cated merged database and were included in the
study.
The clinical charts of women recorded in the data-
base were carefully reviewed by two authors inde-
pendently (CS, GS). All variables reported were
collected on all of the subjects included in this study.
Only singleton gestations who were diagnosed with
superimposed preeclampsia without SF prior to
37weeks were included, as patients diagnosed after
this point were scheduled for delivery, according to
ACOG recommendations [4]. Women with superim-
posed preeclampsia37weeks, and those with super-
imposed preeclampsia with SF or those with multiple
gestations were excluded. Women were also excluded
with known aneuploidy or severe congenital anoma-
lies, if they elected termination, were delivered prior
to 22weeks, or left against medical advice.
Cases were identified by International Classification
of Diseases, 9th Revision for hypertension and preg-
nancy at Thomas Jefferson University. Initial cases
identified included all diagnoses of hypertension with
an associated pregnancy diagnosis. These charts were
individually reviewed to identify patients diagnosed
with superimposed preeclampsia and cross-checked
with a database of all deliveries occurring during the
study period to ensure all cases were captured. In the
Italian center, cases were electronically identified by
using the Hospital general dataset in a prospective
dedicated database for all women referred to the
Department of Reproductive Science, University of
Naples Federico II (Naples, Italy) [5].
In both sites, diagnosis of CHTN and superimposed
preeclampsia were based on the ACOG guidelines [4].
CHTN was defined as either a history of hypertension
preceding the pregnancy or a blood pressure
(BP) 140/90mmHg prior to 20weeks. Superimposed
preeclampsia without SF was defined as a sudden
increase BP that was previously well-controlled or a
need to increase anti-hypertensive requirements, new
onset proteinuria (300mg per 24-h urine collection
protein or >0.3 protein/creatinine ratio each measured
as mg/dL), or a sudden increase in proteinuria in
women who exhibit proteinuria before or early in
pregnancy. Preeclampsia with SF was defined as pre-
eclampsia with any of the following: BP160/
110mmHg four hours apart on bed rest; platelets
<100,000/ll; twice normal concentration of AST or
ALT; creatinine >1.1 (or doubling of the serum creatin-
ine concentration in absence of other renal disease);
pulmonary edema; new-onset cerebral or visual distur-
bances [4].
The decision to manage outpatient or inpatient was
at provider discretion. During the time period studied,
outpatient management was left up to the individual
attending managing the patient, and both outpatient
care and inpatient care were utilized. In order to be a
candidate for outpatient care, there needed to be an
absence of severe features as described above. The
patient also needed to be willing to present frequently
for outpatient assessments and be considered some-
one likely to be compliant with her care. Maternal co-
morbidities and fetal growth restriction were not con-
sidered contraindications to outpatient management
in the cohort studied, but were assessed on an individ-
ual basis. Prior to proteinuria being removed as a cri-
terion for severe disease in 2013, patients with 5 g of
proteinuria in 24 h were occasionally managed as inpa-
tients for solely this reason. They were not delivered
based on that indication alone. Indications for
inpatient and outpatient management by provider did
not change after the 2013 ACOG guidelines. These
determinations were the same for both the
Philadelphia and Naples cohorts.
In cases when outpatient care was selected, fre-
quent follow-up was employed, with a weekly visit
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with a physician or high-risk nurse practitioner, twice
weekly non-stress tests, and a fetal growth ultrasound
every 3–4weeks. Laboratory testing was provider
dependent prior to 2013, but regularly employed
weekly laboratory testing including complete blood
count and a comprehensive metabolic panel after
2013. All patients were counseled on the symptoms of
severe disease and were prescribed a blood pressure
cuff for daily home monitoring of BP. Methyldopa,
labetalol, and nifedipine were the primary agents
chosen to control BP in both outpatient and inpatient
groups. Rarely, amlodipine was used.
Inpatients were managed with twice or three times
daily NST. Umbilical artery (UA) Doppler was per-
formed 1–2 times weekly for intrauterine growth
restriction (IUGR) patients. Indications for delivery
included maternal symptoms or abnormal labs consist-
ent with SF, inability to control BP in the mild range
(SBP<160mm Hg and DBP<110mm Hg) with two
medications, non-reassuring fetal testing, or gesta-
tional age of 37weeks. These indications for delivery
were employed for patients both prior to and after the
2013 ACOG guidelines. Routine delivery at 34weeks
for women with superimposed preeclampsia without
severe features was not employed.
Women who were sent home at any point for out-
patient management were included in the outpatient
treated group (study group). Women in the inpatient
group (comparison group) were all admitted, diag-
nosed with superimposed preeclampsia without SF,
and delivered in one admission. For women included
in the outpatient group who had another admission,
total length of stay was calculated.
The primary outcome was composite maternal mor-
bidity, defined as development of at least one of the
following: severe features, HELLP (hemolysis, elevated
liver enzymes, low platelets) syndrome, placental
abruption, eclampsia, postpartum hemorrhage (defined
as estimated blood loss1000ml for any delivery),
intensive care unit (ICU) admission, or maternal death.
Women with abnormal laboratory values consistent
with severe features as outlined above, but not meet-
ing full requirements for HELLP syndrome (e.g. only
low platelets or only elevated liver enzymes) were clas-
sified as having severe features. Secondary outcomes
were gestational age at delivery, latency (defined as
time from diagnosis to delivery in weeks), mode of
delivery, and neonatal outcomes including birth
weight, small for gestational age (birth weight<10th
percentile), 5-min Apgar <7, admission to neonatal
ICU (NICU), length of stay in NICU, and stillbirth (i.e.
fetal death>22weeks). We assessed the mean differ-
ence in maternal length of stay. Indication for delivery
was recorded, including gestational age 37weeks,
fetal indication (non-reassuring antenatal testing via
NST or BPP, abnormal umbilical artery Doppler), lab
abnormalities consistent with severe features, uncon-
trolled blood pressure, persistent maternal symptoms
as detailed above, or onset of labor.
Statistical analysis was performed using Statistical
Package for Social Sciences (SPSS) v. 19.0 (IBM Inc.,
Armonk, NY). Data are shown as means ± standard
deviation (SD), or as medians (range), or as numbers
(percentage). Univariate comparisons of dichotomous
data were performed with the use of the chi-square or
Fisher’s exact test. Comparisons between groups were
performed with the use of the Mann–Whitney U test,
to test group medians with range; and with the use of
the t-test or the One-way ANOVA to test group means
with SD. Primary and secondary outcomes were esti-
mated with multivariate analyses and also assessed by
site.
Logistic regression, presented as unadjusted odds
ratio (crude OR) or adjusted odds ratio (aOR) with 95%
of confidence interval (CI) [6], was performed.
Adjusted analysis was performed to correct data for
relevant baseline characteristics. Two adjusted analyses
were performed, one in which covariates were
included, if they statistically differed between the
study groups, and one in which all potentially relevant
baseline characteristics were added to the model as
covariates. The latter analysis was performed to show
the robustness of our results [7]. All results presented
in the abstract and text refer to the first adjusted ana-
lysis. Relevant baseline characteristics to be considered
as covariates were: age, BMI, smoking, ethnicity, grav-
idity, parity, prior preeclampsia, diabetes mellitus, prior
medical condition, and IUGR (i.e. ultrasound estimated
fetal weight<10th percentile).
We calculated two-sided p values. A p value<.05
was considered to indicate statistical significance. The
study was approved by the institutional review board
at Thomas Jefferson University Hospital and the
University of Naples Federico II. Data were anonymized
before analysis. This study was reported following the
STROBE guidelines [8].
Results
A total of 365 singleton pregnancies with superim-
posed preeclampsia without SF before 37weeks were
analyzed. 198 (54.2%) were managed outpatient, and
167 (45.8%) as inpatients. The two groups were similar
in terms of maternal demographics except for mean
maternal age (28.4 ± 5.4 versus 32.4 ± 4.1; p¼ .04) and
mean BMI (28.5 ± 6.8 versus 26.0 ± 6.1; p¼ .05). About
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30% in both groups smoked during pregnancy. Most
women in the cohort were white. 60 (30.3%) in the
outpatient group and 49 (29.3%) in the inpatient
group had history of preeclampsia. The mean length
of stay from antepartum through postpartum course
was longer in the inpatient group with a mean differ-
ence of 2.1 days (95%CI 3.7 to 1.6 days). There was
no significant difference in the diagnosis of IUGR
between outpatients and inpatients (9.6% versus
10.8%, p¼ .33) (Table 1).
After adjusting for statistically proven confounders,
we found that there was no statistical difference in
composite maternal morbidity between women man-
aged as outpatients compared to women managed as
inpatient (36.4% versus 41.3%, aOR 0.82, 95%CI
0.55–1.17). There were no eclamptic seizures, HELLP
syndrome or maternal deaths in the cohort. Women
who were managed outpatient had a significantly lon-
ger latency from diagnosis to delivery (mean differ-
ence 14.15 days, 95%CI 8.51–19.41) compared to those
who were managed inpatient. Fetuses from women in
the outpatient group had a significantly higher birth
weight (mean difference 345.34 g, 95%CI
254.11–411.21) and lower risk of SGA (17.7% versus
29.3%; aOR 0.53, 95%CI 0.30–0.84) and of admission to
NICU (40.4% versus 47.9%; aOR 0.72, 95%CI 0.39–0.95)
compared to those from women managed inpatient.
Neonates admitted to the NICU had a shorter length
of stay in the outpatient group by about one week
(mean difference 6.80 days, 95%CI 11.92 to 1.68)
(Table 2). There were no neonatal deaths in the
cohort.
The most common indication for delivery in both
groups was reaching 37weeks gestation. The second
most common indication was uncontrolled BP, fol-
lowed by fetal indications. Indications for delivery are
detailed in Table 3.
There were two stillbirths in the study group (1.0%)
and two in the comparison group (1.2%)
(Supplemental Table). One patient with severe uncon-
trolled HTN throughout pregnancy strongly desired
discharge instead of recommended inpatient manage-
ment. She presented to care after one missed prenatal
visit and one missed ultrasound with a stillbirth. A
second woman managed as an outpatient had a still-
birth. She was a planned outpatient admission until
reaching 24weeks or an estimated fetal weight of
450–500 g prior to administering steroids and inpatient
treatment. This was due to the poor prognosis of early
onset preeclampsia and fetal growth restriction with
abnormal umbilical artery Doppler and reversed a-
wave in the ductus venosus. A stillbirth was diagnosed
at 24weeks. Two additional women were managed as
inpatients and had stillbirths attributed to severe pla-
cental abruption. In both cases emergency cesarean
delivery was performed, with a time from decision to
incision<30min. Both patients had no maternal mor-
bidity from the event.
Discussion
In pregnant singleton gestations with superimposed
preeclampsia without SF, outpatient management had
similar rates of maternal morbidity, and selection of a
low risk group did not lead to a detectable increase in
adverse events. There was an associated longer latency
from diagnosis to delivery and slight improvement in
neonatal outcomes compared to inpatient manage-
ment, likely indicating appropriate selection of a lower
risk cohort. Neonates of women who were managed
as outpatients were significantly less likely to be
admitted to the NICU, though no causal relationship
can be assumed and is presumably due to being an
appropriately selected lower risk group.
Our study has several strengths. This is a large,
high-quality, 7-year cohort study. The number of the
included women is high. Women with high-risk co-
Table 1. Characteristics of the included women.
Outpatient
management
N¼ 198 (54.2%)
Inpatient
management
N¼ 167 (45.0%) p value
Age (years) 28.4 ± 5.4 32.4 ± 4.1 .04
>35 years old 60 (30.3%) 55 (32.9%) .17
BMI (kg/m2) 28.5 ± 6.8 26.0 ± 6.1 .05
>30 kg/m2 68 (34.3%) 65 (38.9%) .58
Smoking 60 (30.3%) 51 (30.5%) .90
Ethnicity
White 138 (69.0%) 110 (65.9%) .81
Black 50 (25.0%) 44 (26.3%) .77
Othera 10 (5.0%) 15 (9.0%) .24
Gravidity 4.2 ± 1.8 3.9 ± 2.0 .76
Median (range) 4 (1–12) 4 (1–12)
Parity 2.8 ± 0.7 2.4 ± 0.9 .64
Median (range) 2 (0–8) 2 (0–7)
Prior preeclampsia 60 (30.3%) 49 (29.3%) .74
Antihypertensive drug use
Started before pregnancy 137 (69.2%) 110 (65.9%) .80
Started during pregnancy 19 (9.8%) 18 (10.8%) .77
None 42 (21.0%) 39 (23.3%) .34
Diabetes mellitus 7 (3.5%) 6 (3.6%) .95
GDM 10 (5.0%) 8 (4.8%) .74
Renal disease 8 (4.0%) 7 (4.2%) .79
Antiphospholipid syndrome 1 (0.5%) 0 .57
Other medical conditionsb 12 (6.1%) 11 (6.6%) .82
GA at diagnosis (weeks) 33.9 ± 4.5 34.9 ± 3.6 .13
IUGR 16 (9.6%) 18 (10.8%) .33
Data are presented as number (percentage) or as mean difference ± stan-
dard deviation or as median (range). Boldface data, statistically significant.
SD: standard deviation; GDM: gestational diabetes mellitus; GA: gesta-
tional age; IUGR: intrauterine growth restriction.
aOther, including Asian and Hispanic.
bPrior medical condition, including thyroid disorders, cardiomyopathy or
valvular disease.
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morbidities were not excluded from this cohort.
Diabetes and obesity are frequent co-morbidities
encountered in a population of women with superim-
posed preeclampsia. Finally, the multicenter nature of
this study makes our results generalizable.
The most important limitation of our study is that
this is a retrospective, non-randomized comparison. A
priori power analysis could not be assessed due to its
retrospective nature [6]; however, the confidence inter-
vals of the odds ratios are quite narrow. The confi-
dence intervals are more statistically useful than post-
hoc power calculations [6]. We acknowledge that
some outcomes were underpowered, particularly pla-
centa abruption, stillbirth, and maternal death.
This data does not necessarily advise a change to
current management practices, especially where
inpatient management is already routine. However, for
institutions where outpatient management is already
in practice, this data can serve as a comparison for
expected outcomes. When considering outpatient
management, there must be a motivated, well-selected
patient to be a partner in care in order to avoid ser-
ious complications, especially stillbirth. Certainly, one
of the stillbirths in the outpatient group was compli-
cated by patient non-adherence to an outpatient sur-
veillance plan, but we were unable to determine if the
recommended surveillance could have prevented that
death. All hypertensive disorders of pregnancy are on
a continuum of severity, and only close surveillance by
both physician and patient can adequately detect and
treat severe disease. The stillbirth rate among all 365
women in the cohort was 1.1% and there were no
neonatal deaths. In a previous cohort that compared
superimposed preeclampsia patients with women who
had preeclampsia without SF, there was a 7% risk of
perinatal death in women with superimposed
preeclampsia [9]. The two stillbirths occurred at
24weeks in fetuses with IUGR and the neonatal deaths
occurred in extremely premature births of<26weeks.
Due to the increased risk in IUGR pregnancies affected
by superimposed preeclampsia, this is likely not an
optimal group for outpatient management once viabil-
ity is reached. Additionally, in that cohort 57% were
delivered for uncontrolled BP and 18% were delivered
for non-reassuring antenatal testing, which is sup-
ported by this study [9]. These are both indications
that can be monitored in an outpatient setting
through home BP monitoring and twice weekly ante-
natal testing.
The limitations of the study for detecting rare out-
comes notwithstanding, if close, vigilant outpatient
care is employed in a well selected population, this
could significantly impact the cost of providing care to
these women.
Conclusions
Due to the retrospective nature of this study, practice
changes should be employed with caution. However,
for those who may already be practicing outpatient
management for superimposed preeclampsia patients
without SF, this does provide data on potential bene-
fits that may be experienced in addition to the risks.
By examining in detail each stillbirth case, some pre-
conditions can be suggested to ensure that only the
most appropriate candidates are offered this type of
care. Patients must have absence of SF as described
above, ideally proved over a prolonged period of mon-
itoring (24 h). An initial evaluation in a hospital setting
is recommended by the ACOG Taskforce on
Hypertension in Pregnancy [4]. If initial evaluation of
the patient and fetus are normal, outpatient manage-
ment can be considered if the patient (a) accepts the
frequent visits necessary to monitor for disease pro-
gression and can perform home monitoring of BP and
symptoms, (b) has the ability to present quickly for
care in the event of disease progression (such as new
maternal symptoms), and (c) lacks significant co-exist-
ing disease in the mother and/or fetus that may pre-
dispose to worse outcomes such as placental
abruption or stillbirth. This would include women who
need further titration of antihypertensive medications,
uncontrolled diabetics, or fetuses with severe growth
restriction or abnormal antenatal testing. Women who
lack the social support for frequent visits or who live
in geographic areas remote from tertiary care centers
should strongly be considered to remain inpatient
until delivery.
Table 3. Indication for delivery.
Outpatient
management
N¼ 198 (54.2%)
Inpatient
management
N¼ 167 (45.8%) p value
37 weeks 65 (32.8%) 50 (29.9%) .60
Fetal indicationa 33 (16.7%) 33 (19.8%) .27
Lab abnormalitiesb 16 (8.1%) 20 (12.0%) .09
Uncontrolled BP 38 (19.2%) 34 (20.4%) .74
Persistent maternal
symptomsc
11 (5.6%) 5 (3.0%) .25
Onset of labor 35 (17.7%) 25 (14.9%) .51
Data are presented as number (percentage).
aFetal indications included non-reassuring features on non-stress test or
continuous monitoring or abnormal umbilical artery Doppler.
bPlatelets<100,000/ll; twice normal concentration of AST or ALT; crea-
tinine>1.1 (or doubling of the serum creatinine concentration in
absence of other renal disease).
cPersistent new-onset cerebral or visual disturbances (e.g. headache, sco-
tomata), nausea or vomiting, abdominal pain, pulmonary edema.
6 C. N. SCHOEN ET AL.
In summary, women with CHTN and superimposed
preeclampsia without SF may be considered as candi-
dates for outpatient care, with the expectation to
achieve similar outcomes to women managed as inpa-
tients. Further study in the form of prospective cohorts
or randomized trials is warranted before large shifts in
clinical practice can be advised.
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